FDA Brief

Warning letters Drugs

FDA warning letter to

Janssen Vaccines Corp., A Johnson & Johnson Company

MediumIssued Jul 18, 2025Posted Sep 23, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Janssen Vaccines over inadequate investigations of stopper complaints and missed regulatory notifications for its injection drug.

What happened

FDA inspected the Incheon drug manufacturing facility from November 11 to 19, 2024. FDA found that Janssen did not thoroughly investigate recurring complaints from November 13, 2023, to November 8, 2024, about stopper events in vials of an injection drug, including one complaint reporting stopper events in four vials from the same batch. FDA also found the quality unit failed to follow procedures for regulatory notification of product quality defects and that responsible officials did not adequately escalate these complaints.

What FDA found

  1. Janssen failed to thoroughly investigate recurring complaints of stopper events in vials of its injection drug, including complaints involving multiple vials and four vials from one batch.

    21 CFR 211.192
  2. Its investigations did not comprehensively assess human-use, manufacturing, and stability factors that could increase the risk of stopper events during use.

    21 CFR 211.192
  3. It did not always sufficiently pursue collection of relevant samples from complainants for investigation.

    21 CFR 211.192
  4. The quality unit did not consistently follow its procedures for regulatory notification of product quality defects, including Biological Product Deviation Reports (BPDRs).

    21 CFR 211.22
  5. Responsible officials did not adequately escalate or act on repeated stopper complaints as required by the company’s procedure.

    21 CFR 211.22

What FDA wants

FDA asks Janssen to respond in writing within 15 working days with corrective actions, including comprehensive assessments and remediation plans for complaint investigations, stopper-event risk, retrospective complaint reviews, and quality-unit oversight. If it cannot complete actions in that time, it must state reasons and a completion schedule.

Who should pay attention

  • drugmakers using contract manufacturers for sterile injectables
  • companies handling vial-stopper or container-closure complaints
  • quality units responsible for BPDR and FAR reporting

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk